Drug Discovery

Twitter

Facebook

Copy Link

Key Facts

Key PlayersIsomorphic Labs, Recursion, Insilico

Top News

AI-Designed Drug Rentosertib Reverses Biological Age by 3-4 Years in Clinical Trial

Insilico Medicine's rentosertib, an AI-generated drug for lung disease, reduced biological age markers by 3-4 years across six proteomic aging clocks in a 42-patient Phase IIa trial. Published in Nature Biotechnology, the study marks the first clinical evaluation of a drug featuring both an AI-discovered target and AI-designed molecule for aging and disease biology.

Health10 sources

AI-Designed Drug Rentosertib Reverses Biological Age by 3-4 Years in Clinical Trial

Health10 sources

Huawei Expands AI Pharma Partnerships Using Domestic Chips Despite Lagging Behind Nvidia

Huawei is expanding AI collaborations with pharmaceutical firms, focusing on domestic Chinese drugmakers using its Ascend and Kunpeng chips. William Zhang, president of Huawei's healthcare business unit, announced plans to deepen partnerships from drug manufacturing to clinical implementation, though the company's disclosed pharma work remains limited compared to Nvidia's billion-dollar partnerships with Eli Lilly and Novo Nordisk.

Business3 sources

Huawei Expands AI Pharma Partnerships Using Domestic Chips Despite Lagging Behind Nvidia

Business3 sources

Google's Gemma AI models surpass one billion downloads with over 100,000 developer variants

Google announced its Gemma family of AI models has crossed one billion downloads, with developers publishing over 100,000 variants in two years. The open-source Gemma AI models now power applications from NASA satellites to India's health infrastructure.

Technology3 sources

Google's Gemma AI models surpass one billion downloads with over 100,000 developer variants

Technology3 sources

AI-Driven Drug-Target Interaction Prediction Shifts From Benchmarks to Real-World Drug Discovery

Chinese researchers published a comprehensive review showing how AI-driven drug-target interaction prediction is evolving from algorithm-focused benchmarks toward practical pharmaceutical research workflows. The study addresses translational barriers including data quality issues and calls for experimentally testable predictions that support candidate screening and drug repurposing.

Science2 sources

AI-Driven Drug-Target Interaction Prediction Shifts From Benchmarks to Real-World Drug Discovery

Science2 sources

Anthropic Claude AI Designs Protein Binders for 14 of 15 Targets in Lab-Validated Breakthrough

Anthropic Claude AI models designed protein binders that succeeded against 14 of 15 targets in independent lab testing by Twist Bioscience and Adaptyv Bio. The campaign achieved 22-35% success rates, surpassing the typical 10-15% range in protein design, while also completing autonomous chemical analysis in minutes.

Technology4 sources

Anthropic Claude AI Designs Protein Binders for 14 of 15 Targets in Lab-Validated Breakthrough

Technology4 sources

TCS Launches ADD AgentHub to Scale Agentic AI Platform Across Pharma Drug Development

Tata Consultancy Services unveiled TCS ADD AgentHub, an enterprise-ready agentic AI platform designed to transform drug development and clinical trials. The platform delivers up to 40% efficiency gains in clinical data management while maintaining regulatory compliance and auditability in highly regulated pharmaceutical environments.

Technology4 sources

TCS Launches ADD AgentHub to Scale Agentic AI Platform Across Pharma Drug Development

Technology4 sources

AI and genetics slash osteoarthritis drug search from 500,000 candidates to 6 in weeks

University of Utah Health researchers combined genetics and AI-based molecular biology to identify M04, a promising new drug for osteoarthritis. The compound reduced inflammation-related genes and promoted joint cell health in lab tests. While M04 hasn't been tested in living organisms, it offers hope for treating OA at its source rather than just managing symptoms.

Health2 sources

AI and genetics slash osteoarthritis drug search from 500,000 candidates to 6 in weeks

Health2 sources

OpenABE gene editor achieves 36x efficiency boost, advancing next-generation gene therapy

Researchers at Sungkyunkwan University developed OpenABE, an AI-designed gene-editing tool that improves editing efficiency by up to 36 times over existing AI models. Using AlphaFold predictions and structure-guided protein engineering, the team created editors that match gold-standard performance while dramatically reducing off-target effects, opening new paths for treating genetic disorders in both nuclear and mitochondrial DNA.

Science2 sources

OpenABE gene editor achieves 36x efficiency boost, advancing next-generation gene therapy

Science2 sources

Google DeepMind dismantles Nobel Prize-winning AlphaFold team in strategic shift to Gemini

Google DeepMind has dismantled the team behind AlphaFold, its Nobel Prize-winning AI system for protein structure prediction. Most original authors have been reassigned to Gemini-focused projects over the past year, while nearly a quarter have left the company. Key scientists including John Jumper have joined rival Anthropic, marking a strategic shift from dedicated research teams to AI-driven scientific research systems.

Business4 sources

Google DeepMind dismantles Nobel Prize-winning AlphaFold team in strategic shift to Gemini

Business4 sources

Trump unveils $5B Genesis Mission AI research grants as White House proposes major science overhaul

The Trump administration announced 278 winning projects from its Genesis Mission, pledging $5 billion for AI-powered research. At the same time, chief science adviser Michael Kratsios released a controversial plan to shift US science funding away from universities toward individual researchers, sparking debate about the future direction of American scientific enterprise.

Policy9 sources

Trump unveils $5B Genesis Mission AI research grants as White House proposes major science overhaul

Policy9 sources

Bristol Myers Squibb deploys Nvidia's most powerful AI system to accelerate drug discovery

Bristol Myers Squibb is building the life sciences industry's most advanced AI infrastructure with Nvidia's DGX SuperPOD based on Vera Rubin architecture. The system delivers 10x more performance per megawatt and already cuts drug testing times by 20-30%, with potential to reach 50% in coming years. The deployment marks a strategic bet on owned compute over rented capacity.

Technology7 sources

Bristol Myers Squibb deploys Nvidia's most powerful AI system to accelerate drug discovery

Technology7 sources

Chai Discovery Raises $400 Million as AI Drug Discovery Moves From Promise to Deployment

Chai Discovery secured $400 million in Series C funding at a $3.8 billion valuation, nearly tripling its worth since December. The AI-driven drug discovery startup has landed partnerships with Pfizer, Eli Lilly, and Novartis, signaling growing investor interest in AI applications for life sciences despite the industry's challenge that no AI-discovered drug has yet received approval.

Startups2 sources

Chai Discovery Raises $400 Million as AI Drug Discovery Moves From Promise to Deployment

Startups2 sources

Stanford's Biomni AI agent autonomously handles complex biomedical research across 10,000+ labs

Stanford researchers unveiled Biomni, an AI agent that autonomously executes biomedical research tasks from hypothesis formation to experimental design. Already deployed in over 10,000 labs, it represents the most widely used AI co-scientist system in biomedicine, completing in 40 minutes what would take researchers 60+ hours.

Science2 sources

Stanford's Biomni AI agent autonomously handles complex biomedical research across 10,000+ labs

Science2 sources

Mindbeam AI uses generative AI to hunt for safer pain meds, tackling acetaminophen toxicity

NVIDIA-backed Mindbeam AI published research showing how generative AI can accelerate drug discovery for safer pain medications. The company evaluated 24 drug candidates targeting the TRPV1 receptor and identified three promising compounds with improved predicted liver safety compared to acetaminophen, which causes roughly half of acute liver failure cases in the U.S.

Health2 sources

Mindbeam AI uses generative AI to hunt for safer pain meds, tackling acetaminophen toxicity

Health2 sources

Nvidia powers AI agents for Silo Pharma and Certara in drug development push

Nvidia is expanding its footprint in pharmaceutical AI as Silo Pharma's subsidiary QwikAgents joins the Nvidia Developer Program and Certara integrates the BioNeMo Agent Toolkit into its drug development platform. The partnerships aim to deploy autonomous AI agents across enterprise workflows and accelerate drug discovery through advanced AI frameworks.

Technology2 sources

Nvidia powers AI agents for Silo Pharma and Certara in drug development push

Technology2 sources

Prev 123 4 5 Next